Menorrhagia and bleeding disorders

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 6, 2007, Pages 513-520

  El Hemaidi, Ihab ^a   Gharaibeh, Amer ^b   Shehata, Hassan ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Menorrhagia; Platelet function disorders; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID; TRANEXAMIC ACID;

AFIBRINOGENEMIA; BERNARD SOULIER DISEASE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG EFFICACY; DYSFIBRINOGENEMIA; FIBRINOGEN DEFECT; GLANZMANN DISEASE; HEALTH SERVICE; HEMOPHILIA A; HETEROZYGOTE; HUMAN; HYPOFIBRINOGENEMIA; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MENORRHAGIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SPLENECTOMY; SURGICAL TECHNIQUE; THROMBOCYTE ANOMALY; THROMBOCYTE TRANSFUSION; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD PLATELET DISORDERS; COMORBIDITY; FEMALE; HUMANS; HYSTERECTOMY; MENORRHAGIA; PLATELET AGGREGATION; VON WILLEBRAND DISEASE;

EID: 36249011307     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f1ddbe     Document Type: Review

References (86)

1. Royal College of Obstetricians and Gynaecologists. The initial management of menorrhagia: evidence based guidelines no. 1. London: Royal College of Obstetricians and Gynaecologists; 1998.
2. Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82:405-422.
3. Corrado M. Women's health in 1990. London: Market & Opinion Research International; 1990.
4. Chief Medical Officers report. London: Department of Health; 2006.
5. Coulter A, Kelland J, Long A. The management of menorrhagia. Effective Healthcare Bull 1995; 9:1-14.
6. Clarke A, Black N, Rowe P, et al. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol 1995; 102:611-620.
7. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertil Steril 2001; 76:125-133.
8. Demers C, Derzko C, David M, Douglas J. Society of Obstetricians and Gynecologists of Canada. Gynaecological and obstetric management of women with inherited bleeding disorders. J Obstet Gynaecol Can 2005; 27:707-732.
9. Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53:234-238.
10. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351:485-489.
11. Kouides PA, Kadir RA. Menorrhagia associated with laboratory abnormalities of hemostasis: epidemiological, diagnostic and therapeutic aspects. J Thromb Haemost 2007; 5 (Suppl 1):175-182. Epidemiological studies have confirmed an association of vWf deficiency and menorrhagia with an incidence of vWf deficiency of 13%. Such patients have a reduced quality of life and incur a high rate of unnecessary gynaecological interventions. Platelet function abnormalities are around three to four-fold more common than vWf deficiency in association with menorrhagia. Management of menorrhagia with an underlying disorder of hemostasis depends on the patient's age, childbearing status and preference in terms of several options. Comparative trials in bleeding disorder-related menorrhagia of intranasal desmopressin, tranexamic acid and the levonorgestrel intrauterine device are ongoing; specific recommendations cannot be made at present.
12. Adcock DM, Jensen R, Johns CS, Macy PA. Coagulation handbook. Austin, Texas: Esoterix Coagulation; 2002.
13. Sadler JE, Mannucci PM, Berntorp E, et al. Impact diagnosis and treatment of von Willebrand disease. Thrombosis Haemostasis 2000; 84:160-174.
14. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97:630-636.
15. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71:520-525.
16. Mazurier C, Ribba AS, Gaucher C, Meyer D. Molecular genetics of von Willebrand disease. Ann Genet 1998; 41:34-43.
17. Peake I, Goodeve A. Type 1 von Willebrand disease. J Thromb Haemost 2007; 5 (Suppl 1):7-11.
18. Sadler JE, Budde U, Eikenboom CJ, et al. The Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4:2103-2114. Certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies. The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future.
19. Simon D, Bandinelli E, Roisenberg I. Polymorphism in the promoter region of von Willebrand factor gene and von Willebrand disease type 1. Genet Mol Biol 2003; 26:397-401.
20. Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand's disease. I: Phenotypic variation within families. Blood 1979; 54:117-136.
21. Nishino M, Yoshioka A. The revised classification of von Willebrand disease including the previously masqueraded female hemophilia A (type 2N). Int J Hematol 1997; 66:21-30.
22. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91:1325-1331.
23. Favaloro EJ, Kershaw G, Bukuya M, et al. Laboratory diagnosis of von Willebrand disorder(vWD) and monitoring of DDAVP therapy: efficacy of PFA100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001; 7:180-189.
24. Favaloro EJ. Utility of PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits, and limitations. Haemophilia 2001; 7:170-179.
25. Hayward CPM, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100_closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312-319.
26. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand disease in pediatric-based population comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84:401-409.
27. Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract Res Clin Haematol 2001; 14:381-399.
28. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111:1236-1240.
29. Conti M, Mari D, Conti E, et al. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68:282-285.
30. Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: guidelines from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10:218-231.
31. Lavabre-Bertrand T, Navarro M, Blanc P, et al. Von Willebrand's disease, digestive angiodysplasia, and estrogen-progesterone treatment. Am J Hematol 1994; 46:254-255.
32. Burgess C, Credland P, Khair K, et al. An evaluation of the usefulness of PFA-100 device in 100 children referred for investigation of potential haemostatic disorder [abstract]. Haemophilia 2001; B247.
33. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114:563-568.
34. Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor dependent agglutination of platelets. J Biol Chem 1991; 266:8149-8155.
35. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58:1033-1036.
36. Mannucci PM, Lusher JM. DDAVP and thrombosis. Lancet 1989; 2:675-676.
37. Nathwani AC, Taddenham EG. Epidemiology of coagulation disorders. Bailliers Clin Haematol 1992; 5:383-439.
38. Peyvandi F, Asselta R, Mannucci PM. Autosomal recessive deficiencies of coagulation factors. Rev Clin Exp Hematol 2001; 5:369-388.
39. Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107:204-206.
40. Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 1978; 51:1223-1228.
41. Kobayashi T, Kanayama N, Tokunaga N, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109: 364-366.
42. Kobayashi T, Kanayama N, Togunaga M, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109:364-366.
43. Evron S, Anteby SO, Brzezinsky A, et al. Congenital afibrinogenemia and recurrent early abortion: a case report. Eur J Obstet Gynecol Reprod Biol 1985; 19:307-311.
44. Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Hematol 1991; 78:571-572.
45. Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936:89-90.
46. Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al. The rare coagulation disorders-review with guidelines for the management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
47. UKHCDO. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9:1-23.
48. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82:1207-1214.
49. Bennett K, Daley ML, Pike C. Factor V deficiency and menstruation: a gynecologic challenge. Obstet Gynecol 1997; 89:839-840.
50. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001; 7 (Suppl. 1):16-22.
51. Borel-Derlon A, Gautier P, Le Querrec A, L'Hirondel JL. Severe congenital factor V deficiency: successful management of bleedings by recombinant factor VIIa [abstract]. Thromb Haemost 1999; 341 (Suppl):1079.
52. Nichols WC, Terry VH, Wheatley MA, et al. ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood 1999; 93:2261-2266.
53. Nichols WC, Seligsohn U, Zivelin A, et al. Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping. J Clin Invest 1997; 99:596-601.
54. Nichols WC, Seligsohn U, Zivelin A, et al. Mutationsin the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998; 93:61-70.
55. Neerman-Arbez M, Johnson KM, Morris MA, et al. Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood 1999; 93:2253-2260.
56. Neerman-Arbez M, Antonarakis SE, Blouin JL, et al. The locus for combined factor V-factor VIII deficiency (F5F8D) maps to 18q21, between D18S849 and D18S1103. Am J Hum Genet 1997; 61:143-150.
57. Ginsburg D, Nichols WC, Zivelin A, et al. Combined factors V and VIII deficiency: the solution. Haemophilia 1998; 4:677-682.
58. Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med 1982; 307:1191-1195.
59. Peyvandi F, Tuddenham EG, Akhtari AM, et al. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998; 100:773-776.
60. Cleton FJ, Loeliger EA. Two typical hereditary charts of congenital factor VII deficiency. Thromb Diath Haemorrh 1980; 17:268-1268.
61. Fadel HE, Krauss JS. Factor VII deficiency and pregnancy. Obstet Gynecol 1989; 73:453-454.
62. Perry DJ. Factor VII deficiency. Br J Haematol 2002; 118:689-700.
63. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98:909-918.
64. Lyon MF. Sex chromatin and gene action in the mammalian x-chromosome. Am J Hum Genet 1962; 14:135-148.
65. Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 1978; 51:1223-1228.
66. Seligsohn U, Modan M. Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection. Isr J Med Sci 1981; 17:413-415.
67. Alhaq A, Mitchell M, Sethi M, et al. Identification of a novel mutation in a non-Jewish factor deficient kindred. Br J Haematol 1999; 104:44-49.
68. Peyvandi F, Lak M, Mannucci P. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica 2002; 87:512-514.
69. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96:293-297.
70. Evans G, Pasi KJ, Mehta A, et al. Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. Blood Coagul Fibrinolysis 1997; 8:437-440.
71. Walker RW, Walker W. Idiopathic thrombocytopenia, initial illness and long term follow up. Arch Dis Child 1984; 59:316-322.
72. Provan D, Newland A, Norfolk D, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura on adults, children, and in pregnancy. Br J Haematol 2003; 120:574-596.
73. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160-174.
74. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990; 94:747-753.
75. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164-171.
76. Reichert N, Seligsohn U, Ramot B. Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases. Thromb Diath Haemorrh 1975; 34:806-820.
77. Agarwal MB, Agarwal UM, Viswanathan C, et al. Glanzmann's thrombasthenia. Ind Pediatr 1992; 29:837-841.
78. Phillips DR, Jenkins CS, Luscher EF, Larrieu M. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature 1975; 257:599-600.
79. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia: evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977; 60:535-545.
80. Hagen I, Nurden A, Bjerrum OJ, et al. Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome. J Clin Invest 1980; 65:722-731.
81. Niessner H, Clemetson KJ, Panzer S, et al. Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies. Blood 1986; 68:571-576.
82. DiMinno G, Coraggio F, Cerbone AM, et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77:157-164.
83. George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984; 311:1084-1098.
84. Nurden AT. Glycoprotein defects responsible for abnormal platelet functions in inherited disorders. In: George JN, Nurden AT, Phillips DR, editors. Platelet membrane glycoproteins. New York: Plenum; 1985. pp. 357-371.
85. Berndt MC, Kabral A, Grimsley P, et al. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 1988; 68:97-101.
86. Cuthbert RJ, Watson HH, Handa SI, et al. DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Res 1988; 110:217-223.